Changes in surface costimulatory molecules such as CD27, CD28, and CD57 reduce the tumor-associated antigen recognition ability of CD8+ T cells, resulting in decreased antitumor activity of CD8+ T cells (85, 86, 106). This evidence concerns the gene CD8A and neoplasm.